Company / Financials
Celldex Therapeutics, Inc. Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$1.5M
FY2025 · -78.0% YoY
Net Income
-$258.8M
FY2025 · -63.9% YoY
Profit Margin
-16748.0%
FY2025 · net income / revenue
ROE
-49.1%
FY2025 · return on equity
Total Assets
$583.0M
FY2025
Total Debt
-
FY2025
Equity
$527.2M
FY2025
ROA
-44.4%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$1.5M-78.0% YoYNet Income HistoryProfit after all expenses and taxes-$258.8M-63.9% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$200.0K0.0% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$287.4M-47.3% YoYSG&A Expense HistorySelling, general, and administrative expenses$43.8M+13.7% YoYR&D Expense HistoryResearch and development spending$245.1M+49.8% YoYInterest Expense HistoryCost of borrowing and debt obligations$927.0KIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$3.90-59.2% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$3.90-59.2% YoY